Board

Alain Huriez, Chairman

Alain is Chairman and Managing Partner of Advent France Biotechnology. Alain brings over 30 years of experience in the Life Sciences sector. Alain’s medical and biotechnological background, experience as an entrepreneur and a leading executive, expertise in clinical development and financing as well as his networks are keys to identifying early-stage biotechnology projects and to mentoring managers into building successful businesses.

Raj Parekh

Raj is a general partner at Advent Life Science, he brings over 20 years of experience in biomedical research and as an entrepreneur and investor.

After gaining an MA and DPhil from Oxford University, he pursued a successful academic career in molecular medicine before co-founding Oxford GlycoSciences (IPO on LSE and NASDAQ). Following its sale to UCB-Celltech, he became Chairman of Galapagos nv, a member of the Supervisory Board of the Novartis Venture Fund and a founding Director of Celldex Therapeutics.

Giuseppina Caligiuri, Scientific Founder

Giuseppina is research director (DR2-HDR) at INSERM U1148 (Cardiovascular Immunobiology at Bichat Hospital in Paris). After an initial training in Medicine and Surgery (Catholic University, Rome, IT), and a PhD in Science (Karolinska Institute, Stockholm, Université Paris VII), Giuseppina developed a research program about immunoregulation in atherothrombosis, rheumatoid arthritis and multiple sclerosis. In 2006, she obtained her Research Leading Habilitation (Faculté de Médecine, Paris V) to work on the role of CD31 in atherosclerosis physiopathology.

Antonino Nicoletti, Scientific Founder, Auditor

Professor of immunology, Deputy head at Insserm U1148, Hôpital Bichat, Paris

Philippe Berthon, CEO

Prior to joining Tridek One, Philippe was CEO of Aurgalys, a corporate finance advisory company he founded in 2008. Aurgalys was sold to Genesta in June 2018. Previously, he was CEO of Vaxon-Biotech, a company that developed anti-cancer immunotherapeutic products. Philippe also founded and led UroGene as a spin-off of his university research laboratory, a company dedicated to urological diseases, including cancer and incontinence. UroGene was sold to the Pierre Fabre Group in early 2005. Prior to these positions, Dr. Berthon was co-founder and director of the Onco-urology Research Laboratory (UPRES 3104) at the Saint-Louis Hospital in Paris, senior postdoc fellow at the Cancer Research Unit, University of York, UK, and Research fellow at Pierre and Marie Curie University. Dr. Berthon has co-authored more than 50 international peer-reviewed publications, obtained his Ph.D. in Reproductive Physiology from Paris Pierre and Marie Curie University, and is a graduate of the Challenge + Business and Administration program at HEC School of Management in Jouy-en-Josas, France. Philippe is also registered financial analyst with the Société Française des Analystes Financiers (SFAF) and an approved Euronext Listing Sponsor.